Stockscreener 앱 받기
24.05
3.34%
-0.83
시간 외 거래:
24.53
0.48
+2.00%
전일 마감가:
$24.88
열려 있는:
$24.67
하루 거래량:
147.91K
Relative Volume:
0.46
시가총액:
$1.56B
수익:
-
순이익/손실:
$-143.59M
주가수익비율:
-8.5175
EPS:
-2.8236
순현금흐름:
$-119.47M
1주 성능:
-8.38%
1개월 성능:
-8.97%
6개월 성능:
+29.30%
1년 성능:
+33.17%
1일 변동 폭
$24.00
$24.67
1주일 범위
$23.62
$28.43
52주 변동 폭
$11.51
$29.80
Pharvaris Nv Stock (PHVS) Company Profile
PHVS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
24.05 | 1.62B | 0 | -143.59M | -119.47M | -2.8236 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-15 | 개시 | H.C. Wainwright | Buy |
| 2025-10-09 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2025-06-11 | 개시 | Guggenheim | Buy |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-09-25 | 개시 | Wedbush | Outperform |
| 2023-08-15 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-05 | 개시 | Bryan Garnier | Buy |
| 2022-09-13 | 재개 | JMP Securities | Mkt Outperform |
| 2022-08-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-22 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-05-25 | 개시 | JMP Securities | Mkt Outperform |
| 2021-03-02 | 개시 | BofA Securities | Neutral |
| 2021-03-02 | 개시 | Morgan Stanley | Overweight |
| 2021-03-02 | 개시 | Oppenheimer | Outperform |
| 2021-03-02 | 개시 | SVB Leerink | Outperform |
모두보기
Pharvaris Nv 주식(PHVS)의 최신 뉴스
Pharvaris (NASDAQ:PHVS) Shares Down 5.7%What's Next? - MarketBeat
What analysts say about Pharvaris NV stockInstitutional Buying Trends & Use Smart Algorithms to Pick Better Stocks - earlytimes.in
CEO Moves: Is Pharvaris NV stock trading near support levelsMarket Performance Report & High Conviction Buy Zone Alerts - moha.gov.vn
Pharvaris (NASDAQ:PHVS) Raised to “Hold” at Wall Street Zen - Defense World
Trading the Move, Not the Narrative: (PHVS) Edition - Stock Traders Daily
Pharvaris (NASDAQ:PHVS) Trading 3.8% Higher – What’s Next? - Defense World
Pharvaris (NASDAQ:PHVS) Shares Up 3.8%Should You Buy? - MarketBeat
Aug Retail: How Pharvaris NV stock responds to policy changesJuly 2025 Weekly Recap & Long-Term Safe Investment Ideas - moha.gov.vn
Pharvaris N.V. (NASDAQ:PHVS) Sees Large Increase in Short Interest - MarketBeat
Pharvaris N.V. (NASDAQ:PHVS) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Pharvaris N.V. (NASDAQ:PHVS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Pharvaris (NASDAQ:PHVS) Shares Down 6.9%Time to Sell? - MarketBeat
Why Pharvaris (PHVS) Is Up 13.3% After RAPIDe-3 Success And 2026 Deucrictibant Filing Plans - Sahm
Behavioral Patterns of PHVS and Institutional Flows - Stock Traders Daily
Pharvaris N.V.(NasdaqGS: PHVS) added to NASDAQ Biotechnology Index - marketscreener.com
What Does Wall Street Think About Pharvaris N.V. (PHVS)? - Insider Monkey
Sentiment Recap: Is Pharvaris NV 9EN stock at risk of policy regulationQuarterly Growth Report & Consistent Return Investment Signals - moha.gov.vn
Why analysts upgrade Pharvaris N.V. stockJuly 2025 Macro Moves & Safe Entry Trade Reports - Улправда
Is Pharvaris N.V. stock trading near support levelsWeekly Volume Report & Risk Managed Investment Signals - DonanımHaber
Aug Final Week: Why analysts upgrade Pharvaris N.V. stockExit Point & Reliable Entry Point Trade Alerts - Улправда
Is Pharvaris N.V. (9EN) stock a momentum leaderJuly 2025 Final Week & Short-Term Trading Opportunity Alerts - Улправда
How geopolitical tensions affect Pharvaris N.V. stockJuly 2025 Opening Moves & Weekly Breakout Watchlists - Улправда
Total debt per share of Pharvaris N.V. – MUN:9EN - TradingView — Track All Markets
Pharvaris (PHVS) Is Down 5.7% After Pivotal RAPIDe-3 Deucrictibant Data And 2026 Filing Plan - Sahm
Pharvaris (NASDAQ:PHVS) Rating Lowered to Sell at Wall Street Zen - Defense World
Pharvaris N.V. $PHVS Shares Bought by TFG Asset Management GP Ltd - MarketBeat
(PHVS) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary AngioedemaSlideshow (NASDAQ:PHVS) 2025-12-09 - Seeking Alpha
This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy? - AOL.com
Pharvaris’ Deucrictibant Provides Rapid Relief for HAE in Phase 3 RAPIDe-3 Trial - HCPLive
Pharvaris stock gains on HAE drug meeting late-stage study goals - MSN
GENERAL ATLANTIC, L.P.'s Pharvaris NV(PHVS) Holding History - GuruFocus
Pharvaris (PHVS): Reassessing Valuation After Strong RAPIDe-3 Phase 3 Success in Hereditary Angioedema - Sahm
Pharvaris N.V. (PHVS) Price Target Increased by 20.90% to 45.73 - Nasdaq
Pharvaris (NASDAQ:PHVS) Given New $30.00 Price Target at Bank of America - MarketBeat
Why Pharvaris N.V. (9EN) stock could outperform next year2025 Retail Activity & Free Daily Entry Point Trade Alerts - Newser
Pharvaris (NASDAQ:PHVS) Price Target Raised to $30.00 at Bank of America - Defense World
B of A Securities Maintains Pharvaris N.V. (PHVS) Neutral Recommendation - Nasdaq
Guggenheim Maintains Pharvaris N.V. (PHVS) Buy Recommendation - Nasdaq
Oppenheimer Maintains Pharvaris N.V. (PHVS) Outperform Recommendation - Nasdaq
Officer Abele Files To Sell 4,109 Of Pharvaris NV [PHVS] - TradingView
Pharvaris N.V. (PHVS) Presents at BSI Clinical Immunology Professional Network (BSI-CIPN) Conference 2025Slideshow (NASDAQ:PHVS) 2025-12-04 - Seeking Alpha
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals - sharewise.com
Is Pharvaris N.V. stock undervalued vs historical averagesWeekly Market Report & Safe Capital Growth Tips - Newser
Pharvaris (NASDAQ:PHVS) Given "Buy" Rating at HC Wainwright - MarketBeat
Pharvaris (NASDAQ:PHVS) Sees Large Volume IncreaseShould You Buy? - MarketBeat
Pharvaris' Phase 3 Trial of Deucrictibant for HAE Attacks Confirms a Differentiated On-Demand Profile, Morgan Stanley Says - marketscreener.com
Will Pharvaris N.V. stock remain a Wall Street favoriteWeekly Trade Review & Free High Accuracy Swing Entry Alerts - Newser
A new trading data show Pharvaris NV (PHVS) is showing positive returns. - setenews.com
Morgan Stanley Raises Price Target on Pharvaris to $41 From $37, Keeps Overweight Rating - MarketScreener
Pharvaris (NASDAQ:PHVS) Sets New 1-Year HighWhat's Next? - MarketBeat
Pharvaris Nv (PHVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.52%
0.07%
자본화:
|
볼륨(24시간):